Abstract
Gastrointestinal (GI) cancers remain one of the most common malignancies and are the second common cause of cancer deaths worldwide. The limited effectiveness of therapy for patients with advanced stage and recurrent disease is a reflection of an incomplete understanding of the molecular basis of GI carcinogenesis. Major advancements have improved our understanding of pathology and pathogenesis of GI cancers, but high mortality rates, unfavorable prognosis and lack of clinical predictive biomarkers provide an impetus to investigate new sensitive and specific diagnostic and prognostic markers for GI cancers. MicroRNAs (miRNAs) are short (19-24 nucleotides) noncoding RNA molecules that regulate gene expression at the posttranscriptional level thus playing an important role in modulating various biological processes including, but not limited to developmental processes, proliferation, apoptosis, metabolism, differentiation, epithelial-mechenchymal transition and are involved in the initiation and progression of various human cancers. Unique miRNA expression profiles have been observed in various cancer types at different stages, suggesting their potential as diagnostic and prognostic biomarkers. Due to their tumor-specific and tissue-specific expression profiles, stability, robust clinical assays for detection in serum as well as in formalin-fixed tissue samples, miRNAs have emerged as attractive candidates for diagnostic and prognostic applications. This review summarizes recent research supporting the utility of miRNAs as novel diagnostic and prognostic tools for GI cancers.
Keywords: Gastrointestinal cancers, diagnosis, prognosis, miRNAs.
Current Pharmaceutical Design
Title:MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Volume: 20 Issue: 33
Author(s): Muzafar A. Macha, Parthasarathy Seshacharyulu, Shiv Ram Krishn, Priya Pai, Satyanarayana Rachagani, Maneesh Jain and Surinder K. Batra
Affiliation:
Keywords: Gastrointestinal cancers, diagnosis, prognosis, miRNAs.
Abstract: Gastrointestinal (GI) cancers remain one of the most common malignancies and are the second common cause of cancer deaths worldwide. The limited effectiveness of therapy for patients with advanced stage and recurrent disease is a reflection of an incomplete understanding of the molecular basis of GI carcinogenesis. Major advancements have improved our understanding of pathology and pathogenesis of GI cancers, but high mortality rates, unfavorable prognosis and lack of clinical predictive biomarkers provide an impetus to investigate new sensitive and specific diagnostic and prognostic markers for GI cancers. MicroRNAs (miRNAs) are short (19-24 nucleotides) noncoding RNA molecules that regulate gene expression at the posttranscriptional level thus playing an important role in modulating various biological processes including, but not limited to developmental processes, proliferation, apoptosis, metabolism, differentiation, epithelial-mechenchymal transition and are involved in the initiation and progression of various human cancers. Unique miRNA expression profiles have been observed in various cancer types at different stages, suggesting their potential as diagnostic and prognostic biomarkers. Due to their tumor-specific and tissue-specific expression profiles, stability, robust clinical assays for detection in serum as well as in formalin-fixed tissue samples, miRNAs have emerged as attractive candidates for diagnostic and prognostic applications. This review summarizes recent research supporting the utility of miRNAs as novel diagnostic and prognostic tools for GI cancers.
Export Options
About this article
Cite this article as:
Macha A. Muzafar, Seshacharyulu Parthasarathy, Krishn Ram Shiv, Pai Priya, Rachagani Satyanarayana, Jain Maneesh and Batra K. Surinder, MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128213117
DOI https://dx.doi.org/10.2174/1381612820666140128213117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies
Recent Patents on Anti-Cancer Drug Discovery Fentanyl for Breakthrough Cancer Pain: Where are We?
Reviews on Recent Clinical Trials Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Amygdalin Decreases Adhesion and Migration of MDA-MB-231 and MCF-7 Breast Cancer Cell Lines
Current Molecular Pharmacology Subject Index to Volume 3
Current Medicinal Chemistry - Central Nervous System Agents Nanocarriers as Prospective Approach in Effective Management of Acne Vulgaris
Micro and Nanosystems Role of Carbon Monoxide in Kidney Function: Is a little Carbon Monoxide Good for the Kidney?
Current Pharmaceutical Biotechnology Novel Insights Into c-Src
Current Pharmaceutical Design Advances on PPARγ Research in the Emerging Era of Precision Medicine
Current Drug Targets Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology Importance of Male Fertility Control in Family Planning
Endocrine, Metabolic & Immune Disorders - Drug Targets An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design Nanoemulsions for Skin Targeting: Present Status and Future Prospects
Drug Delivery Letters Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design The “Gene Cube”: A Novel Approach to Three-dimensional Clustering of Gene Expression Data
Current Bioinformatics Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery